That didn't take long. Healthcare advocates in India decryed the Dehli Court's decision to grant an injunction to Roche blockng sale of Biocon's and Mylan's version of Roche's Herceptin while the court hears Roche's appeal later this month.
The advocacy group says Roche is only tryng to protect its monopoly in India. It furthers stated that Roche's actions prove its contention that MNCs in India want to penalize innovator Indian companies and use biosimilar guidelines to protect its own interests rather than really worry about safety and efficacy of proposed biosimilars.
A Biocon spokesman said, "We are confident that once we are heard by the court, this injunction placing certain limits on promotional activities will not stand."
For the record, Roche says that it is not trying to block the approval of these drugs but simply object to them being called biosimilar versions of Herceptin with what roche terms to be inadequate proof. See The Economic Times.
Posted by Bruce Lehr Feb 10th 2014.